The present invention provides AHR inhibitors, formulations and unit dosage forms thereof, and methods of use thereof.

The present invention provides ophthalmic pharmaceutical compositions of the compound of Formula (I).

##STR(I)##

The present invention provides ophthalmic pharmaceutical compositions of the compound of Formula (I).

##STR(I)##

Provided herein are methods of administering a KRAS G12C inhibitor to a cancer subject.

Provided herein are methods of administering a KRAS G12C inhibitor to a cancer subject.

The present invention relates to: a compound selected from among a novel pyridinyltriazine derivative having protein kinase inhibitory activity, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a stereoisomer thereof; a method for preparing the compound; and a pharmaceutical composition which is for preventing, alleviating, or treating cancer and comprises the compound. A novel compound according to the present invention exhibits excellent inhibitory effects against FGFR, which is a major trigger of bladder cancer, endometrial cancer, etc., point mutations thereof, and various protein kinases other than FGFR involved in signal transduction, and is thus effective as an agent for preventing and treating abnormal cell growth diseases caused by such protein kinases.

Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 infection.

Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 infection.

The present disclosure is directed to FXR agonists, pharmaceutical compositions thereof, and methods of using the same for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis, either alone or in combination with thyroid receptor agonists.

The present disclosure is directed to FXR agonists, pharmaceutical compositions thereof, and methods of using the same for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis, either alone or in combination with thyroid receptor agonists.